PCSA

Processa Pharmaceuticals Inc. (PCSA) | Rumor.io

Processa Pharmaceuticals

PCSA

Attention (50-day avg)0%

Attention rank (50-day avg)#2,253

Bullish sentiment (50-day avg)75%

Price to earnings ratio2.75

Market capitalization5.1M

Earnings per share0.65

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-13.6M

Social

What share of all stock conversation is about PCSA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jul 30

$PCSA is still in a low float situation, with only 6 million shares available for trading, and holders are optimistic about a potential price pump.
The company's recent acquisition of Vidya in a deal leaving existing shareholders with just ~0.9% ownership has resulted in a significant loss of value.
Processa Pharmaceuticals is expected to present P2 Multiple Sclerosis results in 2H28 for VT-7208, which may have a positive impact on the stock price.

Generated by AI

Sentiment

Of the messages about PCSA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	83.29% -10.02
Bearish	—	—	—	16.71% +10.02

Bullish· Jul 29

$PCSA's financing is at a favorable 1.20, which should support the company's growth.
The recent insider buying, including a large number of purchases by the CEO and other executives, suggests confidence in the company's future prospects.
The company's cash runway has been significantly extended, providing a buffer against potential market volatility and allowing for the pursuit of key clinical trials.

Bearish· Jul 29

The company's merger deal may drop the stock to the low $1 range, with a dilution factor of 0.9% only providing $3.4 million for the shell company.
The merger deal has been criticized for being one of the biggest dilution traps of the year, with the company's stock price unable to stay this deep red despite all dilution.
The company's merger deal has been compared to a similar deal with $CMMB, which also promised great things but ultimately tanked the stock, with some investors wondering what the merger actually is and whether it's a good investment opportunity.

Generated by AI

Topics

Of the messages about PCSA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	27.54%
Technical Analysis	—	—	100%	22.95%
Analysts	—	—	0%	23.1%
Controversies	—	—	0%	0.25%
Macro	—	—	0%	25.65%
Earnings	—	—	0%	0.51%

Announcements· Jul 29

Processa Pharmaceuticals has acquired Vidya Therapeutics in a reverse merger, with Vidya's BTK inhibitor VT-7208 to be advanced through Phase 2 trials.
The acquisition is supported by a $200 million concurrent private placement, with PIPE investors to own 52.6% of the company post-close.
The deal aims to advance VT-7208, a next-generation brain-penetrant BTK inhibitor for food allergy, CSU, and MS, with trials expected to continue into 2029.

Technical Analysis· Apr 2

$PCSA decisively breaches the $2.80 resistance on +19.48% surge, targeting $3.93 as momentum accelerates.
Volume confirms institutional interest in the breakout structure, with spikes ranging from 106.37K to 127.82K.
News catalysts, including the J.P. Morgan Healthcare Conference, align with the powerful surges, projecting technical targets ranging from $3.88 to $4.16.

Generated by AI

Community

Of the messages about PCSA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0.92%	20.23%
Newcomers	—	—	99.08%	79.77%

Regulars· Jul 29

Processa Pharmaceuticals' merger with Vidya Therapeutics is complete, with Processa issuing 558,398 shares of common stock and 142,744 shares of Series A Preferred Stock to Vidya's stockholders.
The merger is seen as a way for Processa to advance its BTK inhibitor, VT-7208, in multiple disease areas, with Vidya's phase 1 data suggesting VT-7208 could be administered at lower doses than earlier BTK inhibitors.
Processa's management and board of directors have received substantial options to purchase shares at $4.96, with some receiving millions of shares, leading to accusations of unjust enrichment and greed at the expense of shareholders.

Newcomers· Jul 30

The newcomers are optimistic about Processa Pharmaceuticals, Inc. ($PCSA) breaking through the $2 mark and are expecting a significant price increase.
They are discussing the low float of $PCSA, with some speculating that the company's acquisition of Vidya and the subsequent dilution of shares may have contributed to the low volume.
The newcomers are also focused on the recent price action of $PCSA, with some noting that the stock's massive green candle at the end of the trading day may be a sign of a reversal.

Generated by AI

News

Processa Pharmaceuticals at H.C. Wainwright: bets on vt-7208

18d agoInvesting.com

Processa Pharmaceuticals at wells fargo healthcare conference: cash fuels vt-7208 push

19d agoInvesting.com

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

VERO BEACH, FL, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases, today announced its participation in two upcoming investor conferences. Sheila Gujrathi, M.D., a member of the Processa board of directors and founder and former executive chair of Vidya Therapeutics, will give a company presentation at the following: Thursday,

29d agoYahoo Finance

Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting

1mo agoInvesting.com

Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections

1mo agoInvesting.com

Processa Pharmaceuticals acquires Vidya, raises strategic funding

Detailed price information for Processa Pharmaceuticals Inc (PCSA-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about PCSA also mention

#	Name	Attention
1	Mangoceuticals, Inc.MGRX	0%0
2	Splash Beverage Group Inc.SBEV	0%new
3	Intensity Therapeutics, Inc.INTS	0%0
4	Intelligent Bio Solutions Inc.INBS	0%0
5	Ryvyl Inc.RVYL	0%0
6	Femasys Inc.FEMY	0%+0
7	AtlasClear Holdings, Inc.ATCH	0.01%0
8	Dogwood Therapeutics Inc.VIRI	0%0
9	Onconetix Inc.ONCO	0%-0.02
10	ABP - Abpro Corporation	——

Processa Pharmaceuticals Inc.

Healthcare
Biotechnology

Processa Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation chemotherapy and other therapies for serious diseases with high unmet medical needs. The company’s current portfolio centers on oncology programs designed to improve the safety and efficacy of existing cancer treatments by modifying how approved drugs are metabolized and distributed while preserving their cancer-killing mechanisms. Its pipeline also includes non-oncology candidates for conditions such as gastroparesis and glomerular disease. Processa Pharmaceuticals uses a regulatory science-driven approach to advance drug candidates that aim to offer better treatment options for patients facing complex medical conditions. Headquartered in Vero Beach, Florida, Processa Pharmaceuticals participates in the broader pharmaceutical innovation market through research, clinical development, and product pipeline advancement.

Website

Location

601 21st Street

Vero Beach, FL, 32960

United States

Social

What share of all stock conversation is about PCSA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jul 30

$PCSA is still in a low float situation, with only 6 million shares available for trading, and holders are optimistic about a potential price pump.
The company's recent acquisition of Vidya in a deal leaving existing shareholders with just ~0.9% ownership has resulted in a significant loss of value.
Processa Pharmaceuticals is expected to present P2 Multiple Sclerosis results in 2H28 for VT-7208, which may have a positive impact on the stock price.

Generated by AI

Sentiment

Of the messages about PCSA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	83.29% -10.02
Bearish	—	—	—	16.71% +10.02

Bullish· Jul 29

$PCSA's financing is at a favorable 1.20, which should support the company's growth.
The recent insider buying, including a large number of purchases by the CEO and other executives, suggests confidence in the company's future prospects.
The company's cash runway has been significantly extended, providing a buffer against potential market volatility and allowing for the pursuit of key clinical trials.

Bearish· Jul 29

The company's merger deal may drop the stock to the low $1 range, with a dilution factor of 0.9% only providing $3.4 million for the shell company.
The merger deal has been criticized for being one of the biggest dilution traps of the year, with the company's stock price unable to stay this deep red despite all dilution.
The company's merger deal has been compared to a similar deal with $CMMB, which also promised great things but ultimately tanked the stock, with some investors wondering what the merger actually is and whether it's a good investment opportunity.

Generated by AI

Topics

Of the messages about PCSA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	27.54%
Technical Analysis	—	—	100%	22.95%
Analysts	—	—	0%	23.1%
Controversies	—	—	0%	0.25%
Macro	—	—	0%	25.65%
Earnings	—	—	0%	0.51%

Announcements· Jul 29

Processa Pharmaceuticals has acquired Vidya Therapeutics in a reverse merger, with Vidya's BTK inhibitor VT-7208 to be advanced through Phase 2 trials.
The acquisition is supported by a $200 million concurrent private placement, with PIPE investors to own 52.6% of the company post-close.
The deal aims to advance VT-7208, a next-generation brain-penetrant BTK inhibitor for food allergy, CSU, and MS, with trials expected to continue into 2029.

Technical Analysis· Apr 2

$PCSA decisively breaches the $2.80 resistance on +19.48% surge, targeting $3.93 as momentum accelerates.
Volume confirms institutional interest in the breakout structure, with spikes ranging from 106.37K to 127.82K.
News catalysts, including the J.P. Morgan Healthcare Conference, align with the powerful surges, projecting technical targets ranging from $3.88 to $4.16.

Generated by AI

Community

Of the messages about PCSA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0.92%	20.23%
Newcomers	—	—	99.08%	79.77%

Regulars· Jul 29

Processa Pharmaceuticals' merger with Vidya Therapeutics is complete, with Processa issuing 558,398 shares of common stock and 142,744 shares of Series A Preferred Stock to Vidya's stockholders.
The merger is seen as a way for Processa to advance its BTK inhibitor, VT-7208, in multiple disease areas, with Vidya's phase 1 data suggesting VT-7208 could be administered at lower doses than earlier BTK inhibitors.
Processa's management and board of directors have received substantial options to purchase shares at $4.96, with some receiving millions of shares, leading to accusations of unjust enrichment and greed at the expense of shareholders.

Newcomers· Jul 30

The newcomers are optimistic about Processa Pharmaceuticals, Inc. ($PCSA) breaking through the $2 mark and are expecting a significant price increase.
They are discussing the low float of $PCSA, with some speculating that the company's acquisition of Vidya and the subsequent dilution of shares may have contributed to the low volume.
The newcomers are also focused on the recent price action of $PCSA, with some noting that the stock's massive green candle at the end of the trading day may be a sign of a reversal.

Generated by AI

Processa Pharmaceuticals

Social

Jul 30

Bullish· Jul 29

Bearish· Jul 29

Announcements· Jul 29

Technical Analysis· Apr 2

Regulars· Jul 29

Newcomers· Jul 30

Processa Pharmaceuticals at H.C. Wainwright: bets on vt-7208

Processa Pharmaceuticals at wells fargo healthcare conference: cash fuels vt-7208 push

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting

Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections

Processa Pharmaceuticals acquires Vidya, raises strategic funding

Also Discussed

Processa Pharmaceuticals Inc.

Company Information

Location

Processa Pharmaceuticals at H.C. Wainwright: bets on vt-7208

Processa Pharmaceuticals at wells fargo healthcare conference: cash fuels vt-7208 push

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting

Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections

Processa Pharmaceuticals acquires Vidya, raises strategic funding

Also Discussed

Social

Jul 30

Bullish· Jul 29

Bearish· Jul 29

Announcements· Jul 29

Technical Analysis· Apr 2

Regulars· Jul 29

Newcomers· Jul 30